EGFR L833F + EGFR L861Q
|
NSCLC
|
EGFR L833F + EGFR L861Q
|
NSCLC
|
afatinib Resistant: C4 – Case Studies
|
afatinib Resistant: C4 – Case Studies
|
EGFR L833F + EGFR L861Q
|
NSCLC
|
EGFR L833F + EGFR L861Q
|
NSCLC
|
bevacizumab + osimertinib Sensitive: C4 – Case Studies
|
bevacizumab + osimertinib Sensitive: C4 – Case Studies
|